Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Solid Malignancies × Fulvestrant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 107 Neoplasm Metastasis 13 Neoplasms 12 Multiple Endocrine Neoplasia Type 1 5 Advanced Breast Cancer 5 Prostatic Neoplasms 3 Hereditary Sensory and Autonomic Neuropathies 3 Recurrence 2 Lymphoma 2 Lung Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Cancer Metastatic 2 Solid Malignancies 1 Small Cell Lung Carcinoma 1 Sex Cord-Gonadal Stromal Tumors 1 Sarcoma, Endometrial Stromal 1 Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1 Patient Acceptance of Health Care 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasms by Site 1 Mesothelioma, Malignant 1 Mesothelioma 1 Lymphoma, Non-Hodgkin 1 Lethal Congenital Contracture Syndrome 2 1 Hyperglycemia 1 Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1

Interventions

ixabepilone 1 ST 1481 1 Paclitaxel 1 Fulvestrant 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02640755 2019-04-22

14C

AstraZeneca

Phase 1 Completed

4 enrolled 34 charts

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡